Loading...
•
Mar 31, 2021
PTC Therapeutics Q1 2021 Earnings Report
PTC Therapeutics reported strong Q1 2021 results with significant revenue growth and progress in clinical trials.
Key Takeaways
PTC Therapeutics announced a strong first quarter with total revenue of $117.9 million, a 73% increase over Q1 2020. The DMD franchise contributed $90 million, driven by Translarna and Emflaza. The company also highlighted positive preliminary results in the PTC518 Huntington’s disease program.
Total revenue reached $117.9 million, up 73% from Q1 2020.
DMD franchise revenue was $90 million, a 32% increase year-over-year.
PTC518 Phase 1 trial showed dose-dependent reduction of Huntington mRNA.
Evrysdi's first EU sale triggered a $20 million milestone payment.
PTC Therapeutics
PTC Therapeutics
PTC Therapeutics Revenue by Segment
Revenue by Segment
Translarna Revenue
CapyFin.comEmflaza Revenue
CapyFin.comDMD Franchise Revenue
CapyFin.com Forward Guidance
PTC reaffirms its full year 2021 guidance.
Positive Outlook
- Net product revenues for the DMD franchise for the full year 2021 to be between $355 and $375 million.
- PTC anticipates GAAP R&D and SG&A expense for the full year 2021 to be between $825 and $855 million.
- PTC anticipates Non-GAAP R&D and SG&A expense for the full year 2021 to be between $725 and $755 million, excluding estimated non-cash, stock-based compensation expense of $100 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income